Factors Related to Paclitaxel Hypersensitivity Among Lung Cancer Patients Receiving Chemotherapy at Outpatient Chemotherapy Unit 1 Maharaj Nakorn Chiang Mai Hospital
Keywords:
Hypersensitivity, Lung cancer, Paclitaxel, ChemotherapyAbstract
Patients with lung cancer who receive Paclitaxel chemotherapy are more likely to develop hypersensitivity while receiving this drug. Nurses have a role in assessing and monitoring the occurrence of hypersensitivity during drug administration. This retrospective chart review study examined factors related to Paclitaxel hypersensitivity among lung cancer patients who received chemotherapy from January 2014 to December 2019. The sample consisted of 240 patients with lung cancer who received Paclitaxel chemotherapy; 56 experienced Paclitaxel hypersensitivity, and 184 did not develop a hypersensitive reaction. Data were analyzed by chi-square correlation and logistic regression.
The results showed that factors related to Paclitaxel hypersensitivity were gender, age, and cycle of chemotherapy (p = .009, p = .021 and p < .001). Females were 2.81 times more likely to develop hypersensitive reaction than males (95% CI 1.29 – 6.11). People over 60 were 2.60 times more likely to develop a hypersensitive reaction than those under 60 (95% CI 1.15 – 5.86). Those who received cycle 1 were 5.67 times more likely to develop a hypersensitive reaction than those who received cycle 3 (95% CI 1.80 - 17.89), and those who received cycle 2 were 34.39 times more likely than those who received cycle 3 (95% CI 12.41 - 95.33).
Findings from this study provide information for nurses to assess monitoring and to develop a screening tool for hypersensitivity while receiving Paclitaxel chemotherapy.
References
BC Cancer Provincial Pharmacy (2012). BC cancer drug manual: Paclitaxel. Page 11. Retrieved from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Paclitaxel_monograph.pdf
Bonamichi-Santos, R., & Castells, M. (2018). Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: Reactions to Taxanes and Monoclonal antibodies. Clinical Reviews in Allergy & Immunology, 54(1), 375–385
Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., & Masse, S. M. S. (2014). Management of hypersensitivity to platinum and Taxane based chemotherapy: Cepo review and clinical recommendations. Current Oncology, 21(4), e630-e641.
Foongfaung, S. (2018). Nursing management of hypersensitivity and infusion reactions from intravenously administered chemotherapeutic agents. Thai Cancer Journal, 38(1), 29 - 41.
Garon, E.B., & Dubinett, S.M. (2011). Mitotic inhibitors. Journal of Thoracic Oncology, 6(11 Suppl 4), S1791-S1792.
Grabowski, J. P., Richter, R., Rittmeister, H., Chekerov, R., Wooopen, H., & Sehoul, J. (2018). Impact of body mass index (BMI) on chemotherapy-associated toxicity in ovarian cancer patients. A pooled analysis of the north-eastern German society of gynecological oncology (NOGGO) databank on 1,213 patients. Anticancer Research, 38, 5853-5858.
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., & Unger, J. (2016). Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest oncology group clinical trials. Journal of Clinical Oncology, 34(25), 3014-3022.
Insamran, W., & Sangrajrang, S. (2020). National cancer control program of Thailand. Asia Pacific Journal of Cancer Prevention, 21(3), 577-582. doi:10.31557/APJCP.2020.21.3.577
Jhankumpha, S., Sareelae, N., Sararat, C., Kumdang, S., & Panawong, S. (2019). Factors related to hypersensitivity reactions of cancer patients with receiving paclitaxel chemotherapy. Journal of Health Nursing and Education, 2 (3), 43 -54.
Kwon, J. S., Elit, L., Finn, M., Hirte, H., Mazurka, J., Moens, F., … Trim, K. (2002). A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecologic Oncology, 84(1), 420–425.
Kumsopha, N., & Hongthai, S. (2018) A comparative study of hypersensitivity reaction between slow rate infusion and usual rate in cancer patients receiving Taxanes. Retrieved from http://www.cbh.moph.go.th/app/intranet/files/km/1507177052_1.%E0%B8%99%E0%B8%A7%E0%B8%A5%E0%B8%AD%E0%B8%99%E0%B8%87%E0%B8%84%E0%B9%8C%20%E0%B8%84%E0%B8%B3%E0%B9%82%E0%B8%AA%E0%B8%A0%E0%B8%B2.pdf
Loissaratrakul, N., Udomphol, N., & Panna, P. (2019). Incidence and risk factors for paclitaxel hypersensitivity in cancer chemotherapy. Thai Cancer Journal, 39(4), 143-152.
Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., … Macciò, A. (2018). Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. Frontier in Physiology, 9(1), 1-20.
Maleehuan, O., Wangnum, K., Maneejavakajorn, J., & Laohavinij, S. (2016). Factors related of hypersensitivity reactions with lung cancer patients receiving chemotherapy in paclitaxel. Journal of The Department of Medical Services, 41(4), 105-117. (in Thai)
Medical Record and Statistics Section. (2020). Statistical report of lung cancer Maharaj Nakorn Chiang Mai Hospital. Chiang Mai: Faculty of Medicine. (in Thai)
Mertes, P. M., Demoly, P., & Malinovsky, J. M. (2021). Hypersensitivity reactions in the anesthesia setting/allergic reactions to anesthetics. Current Opinion in Allergy and Clinical Immunology, 12(4), 361-368.
Muallaoglu, S., Disel, U., Mertsoylu, H., Besen, A., Karadeniz, C., Sumbul, A. T., … Ozyilkan, O. (2013). Acute infusion reactions to chemotherapeutic drugs: A single institute experience. Journal of the Balkan Union of Oncology, 18(1), 261-267.
National Cancer Institute. (2017). Common terminology criteria for adverse events (CTCAE) version 5.0. United States of America, Department of Health and Human Services. Retrieved from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/
docs/ ctcae_v5_quick_reference_5x7.pdf
National Cancer Institute, Department of Medical Services, Ministry of Public Health. (2015). Guidelines for the diagnosis and treatment of lung cancer (2nd update, 1st ed). Bangkok: Kosit Printing. (in Thai)
Piovano, E., Pivetta, E., Modaffari, P., Martra, F., Baima Poma, C., Perotto, S., … Ferrero, A. (2012) A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecologic and Obstetric Investigation, 74, 21–27.
Pagani, M., Bavbek, S., Alvarez-Cuesta, E., Dursun, A. B., Bonadonna, P., Castells, M., … Sanchez, S. S. (2021). Hypersensitivity reactions to chemotherapy: An EAACI position paper. Allergy, 77, 388–403.
Sendo, T., Sakai, N., Itoh, Y., Ikesue, H., Kobayashi, H., Hirakawa, T., … Oishi R. (2005). Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemotherapy and Pharmacology, 56, 91-96. doi: 10.1007/s00280-004-0924-9
Tai, Y. H., Tai, Y. J., Hsu, H. C., Lee, S. P., Chen, Y.Y., Chiang, Y.C., … Cheng, W. F. (2017). Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Frontiers in Pharmacology, 8, 1-8.
Tangsaghasaksri, R., & Jainan, P. (2018). Incidence of hypersensitivity reactions from Paclitaxel. Journal of the Medical Association of Thailand, 101 (Suppl. 2), S150-S154.
Tevichai, S. (2016). Epidemiology of hypersensitivity from the use of paclitaxel in Lampang Cancer Hospital, 2013-2015. Lampang Cancer Hospital Brochure, 22(65), 1-7.
Tije, A. J., Smorenburga, C .H., Seynaevea, C., Sparrebooma, A., Schothorst, K. L. C., Kerkhofs, L. G. M., … Verweij, J. (2004). Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. European Journal of Cancer, 40, 352–357.
Vanichbuncha, K. (2016). Statistical analysis: Statistics for administration and research. Bangkok: Chulalongkorn University Printing House.
Vogel, W. H. (2010). Infusion reactions: Diagnosis, assessment, and management. Clinical Journal of Oncology Nursing, 14(2), E10–E21. doi.org/10.1188/10.CJON.E10-E21
World Health Organization [WHO]. (2021). Cancer. Retrieved fromhttps://www.who.int/news-room/fact-sheets/detail/cancer
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Nursing Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารพยาบาลสาร
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับมหาวิทยาลัยเชียงใหม่ และคณาจารย์ท่านอื่นๆในมหาวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
